CANNABIS
Dronabinol does not cause metabolic disturbances in managing chronic neuropathy pain
Clin Ther. 2015 Oct 1;37(10):2267-74. doi: 10.1016/j.clinthera.2015.07.02313 patients diagnosed with non-cardiac chest pain were randomly assigned to orally consume twice a day for 4 weeks either 5mg dronabinol capsules or placebo capsules. Metabolic parameters such as body mass index, various cholesterol levels, triglyceride level, plasma glucose level, insulin and leptin level, and high-sensitivity C-reactive protein level were assessed at the beginning and end of the 4-week treatment period. Results demonstrated no significant change in any metabolic parameters, suggesting that dronabinol may be used for pain management without metabolic disturbances.
Unlock the full ACE Report
You have access to {0} free articles per month.Click below to unlock and view this {1}
Unlock NowCritical appraisals of the latest, high-impact randomized controlled trials and systematic reviews in orthopaedics
Access to OrthoEvidence podcast content, including collaborations with the Journal of Bone and Joint Surgery, interviews with internationally recognized surgeons, and roundtable discussions on orthopaedic news and topics
Subscription to The Pulse, a twice-weekly evidence-based newsletter designed to help you make better clinical decisions
Exclusive access to original content articles, including in-house systematic reviews, and articles on health research methods and hot orthopaedic topics
Or upgrade today and gain access to all OrthoEvidence content for just $1.99 per week.
Already have an account? Log in
Subscribe to "The Pulse"
Evidence-Based Orthopaedics direct to your inbox.
{0} of {1} free articles
Become an OrthoEvidence Premium Member. Expand your perspective with high-quality evidence.
Upgrade Now
